These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 33609232)

  • 21. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
    Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
    Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis.
    Yarborough BJ; Stumbo SP; McCarty D; Mertens J; Weisner C; Green CA
    Drug Alcohol Depend; 2016 Mar; 160():112-8. PubMed ID: 26796596
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up assessment of opioid use outcomes among individuals with comorbid mental disorders and opioid use disorder treated with buprenorphine or methadone in a randomized clinical trial.
    Hser YI; Zhu Y; Fei Z; Mooney LJ; Evans EA; Kelleghan A; Matthews A; Yoo C; Saxon AJ
    Addiction; 2022 Jan; 117(1):151-161. PubMed ID: 34105213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pain Management Considerations in Patients With Opioid Use Disorder Requiring Critical Care.
    Smith K; Wang M; Abdukalikov R; McAullife A; Whitesell D; Richard J; Sauer W; Quaye A
    J Clin Pharmacol; 2022 Apr; 62(4):449-462. PubMed ID: 34775634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of buprenorphine vs methadone on sleep breathing disorders.
    Adimi Naghan P; Setareh J; Malekmohammad M
    Adv Respir Med; 2021; 89(4):439-443. PubMed ID: 33871044
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for opioid overdose and awareness of overdose risk among veterans prescribed chronic opioids for addiction or pain.
    Wilder CM; Miller SC; Tiffany E; Winhusen T; Winstanley EL; Stein MD
    J Addict Dis; 2016; 35(1):42-51. PubMed ID: 26566771
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The problem of pain: Additive analgesic effect of tramadol and buprenorphine in a patient with opioid use disorder.
    Montalvo C; Genovese N; Renner J
    Subst Abus; 2019; 40(2):136-139. PubMed ID: 30835647
    [No Abstract]   [Full Text] [Related]  

  • 29. Nonmedical use of gabapentin and opioid agonist medications in treatment-seeking individuals with opioid use disorder.
    Ellis MS; Buttram ME; Kasper ZA
    Drug Alcohol Depend; 2022 May; 234():109400. PubMed ID: 35290917
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "I'm a Survivor": Perceptions of Chronic Disease and Survivorship Among Individuals in Long-Term Remission from Opioid Use Disorder.
    Pytell JD; Sklar MD; Carrese J; Rastegar DA; Gunn C; Chander G
    J Gen Intern Med; 2022 Feb; 37(3):593-600. PubMed ID: 34027611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The OPTIMA study, buprenorphine/naloxone and methadone models of care for the treatment of prescription opioid use disorder: Study design and rationale.
    Socias ME; Ahamad K; Le Foll B; Lim R; Bruneau J; Fischer B; Wild TC; Wood E; Jutras-Aswad D
    Contemp Clin Trials; 2018 Jun; 69():21-27. PubMed ID: 29627621
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treating Women Who Are Pregnant and Parenting for Opioid Use Disorder and the Concurrent Care of Their Infants and Children: Literature Review to Support National Guidance.
    Klaman SL; Isaacs K; Leopold A; Perpich J; Hayashi S; Vender J; Campopiano M; Jones HE
    J Addict Med; 2017; 11(3):178-190. PubMed ID: 28406856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder.
    Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM
    JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Consumer attitudes about opioid addiction treatment: a focus group study in New York City.
    Sohler NL; Weiss L; Egan JE; López CM; Favaro J; Cordero R; Cunningham CO
    J Opioid Manag; 2013; 9(2):111-9. PubMed ID: 23709320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Readiness and recovery: Transferring between methadone and buprenorphine/naloxone for the treatment of opioid use disorder.
    Bishop B; Gilmour J; Deering D
    Int J Ment Health Nurs; 2019 Feb; 28(1):226-236. PubMed ID: 30019812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. "
    Checkley L; Steiger S; Knight KR
    Subst Abus; 2022; 43(1):767-773. PubMed ID: 35112998
    [No Abstract]   [Full Text] [Related]  

  • 37. Psychiatric comorbidity and treatment outcomes in patients with opioid use disorder: Results from a multisite trial of buprenorphine-naloxone and methadone.
    Zhu Y; Mooney LJ; Yoo C; Evans EA; Kelleghan A; Saxon AJ; Curtis ME; Hser YI
    Drug Alcohol Depend; 2021 Nov; 228():108996. PubMed ID: 34555691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: clinical summary for family physicians. Part 2: special populations.
    Kahan M; Wilson L; Mailis-Gagnon A; Srivastava A;
    Can Fam Physician; 2011 Nov; 57(11):1269-76, e419-28. PubMed ID: 22084456
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spatial proximity and access to buprenorphine or methadone treatment for opioid use disorder in a sample of people misusing opioids in Southern California.
    Davidson PJ; Bowles JM; Faul M; Gaines TL
    J Subst Abuse Treat; 2022 Jan; 132():108634. PubMed ID: 34625318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion of chronic pain patients from full-opioid agonists to sublingual buprenorphine.
    Daitch J; Frey ME; Silver D; Mitnick C; Daitch D; Pergolizzi J
    Pain Physician; 2012 Jul; 15(3 Suppl):ES59-66. PubMed ID: 22786462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.